GHP Q2 2023

Q2 2023 At-Home DNA Testing: Know Yourself Better in Four Steps Dedicated to improving the health, wellness, and beauty of individuals across the world, Dynamic DNA Laboratories is a biotechnology company offering DNA testing products that analyse customers’ genetic code to provide a comprehensive insight into their health, nutrition, and fitness. For its outstanding products and services, the company is proud to have won Best Supplier of At-Home DNA Testing Kits in the GHP Global Excellence Awards 2023. Featuring:

Welcome to the Q2 edition of Global Health & Pharma Magazine 2023, providing you with all of the latest news and features from across the healthcare and pharmaceutical landscape. Q2 2023 As we find ourselves half way through the year already, we have so many exciting developments to share with you. In this issue, we’re pleased to be featuring an array of innovative companies delivering cutting-edge solutions for healthcare providers, whether practice management software, an orthopaedic medical device, or healthcare informatics digital platform. Each is designed to enable the utmost efficiency and an excellent experience for patients. Then there are those outstanding companies providing services and products for individuals who need them, such as online mindfulness training, home care, dental treatments, earwax removal, skincare, as well as a nutritional drink supplement, all developed to contribute to the best quality of life possible. And on our front cover, we’re delighted to be featuring Dynamic DNA Laboratories, who we’ve named as Best Supplier of At-Home DNA Testing Kits. Operating within its hi-tech genetics, microbiology, cellular, and microscopy laboratory, the Dynamic DNA team specialise in advanced DNA testing and strive to promote positive change by helping people better understand themselves. All it takes is a cheek swab and the company can help you learn more about your ancestry and health by analysing your genetic code. We hope you find this issue to be informative and insightful and wish you a prosperous quarter ahead. In the meantime, we looking forward to welcoming you back again for Q3 issue. Rebecca Scotland, Editor Website: AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.

Contents 4. News 6. Dynamic DNA Laboratories: At-Home DNA Testing: Know Yourself Better in Four Steps 8. Creasallis: Game-Changing Antibody Solutions 9. Clinisys: Transforming Laboratories Globally 10. Aiberry: The Future of Mental Health Assessment: AI-Powered Screening 11. Therapy Brands: Practice management software made easy. 12. Western Fjords Advanced Technologies LLC: Most Innovative Novel Therapeutics Developer 2023 - Nordics 14. Clearwax Ltd: Best Ear Care Professionals, Technology, and Clinical Evidence 15. OSSIO: Naturally Transformative Bone Healing. 16. Totally Derma® (Boley Nutraceuticals Ltd): Totally Derma®: Changing Lives Through Nutrition 17. Mindfulness Educators® - Mediacom srl: Best Online Mindfulness Training Course 2023 18. Dental101 Pty Ltd: Dental Education and Knowledge for Students and Graduates 20. Cosmetic Tattoo Clinic: Start an exciting new career in Semi-Permanent Makeup. 21. IHI Care Services: Best Home Care Services Provider 2023 – UK 22. Mill Hill Dental Practice London: Your Smile Matters 23. Craniosacrale Traumatherapie: The Power of Gentle Self-Healing 24. CE.way Regulatory Consultants: Cosmetics regulatory and testing solutions. 25. Dr Joshua Harley Street Aesthetics: With Subtlety Comes Beauty 26. Myllia Biotechnology: Single-cell CRISPR Screens Enabling Drug Discovery 28. Maison Aesthetique: Devon’s Best Specialist Skin Rejuvenation Clinic 29. Premier Veins: Patient-tailored Treatments for Varicose Veins and Thread Veins 30. Verista, Inc.: Leading Life Sciences Business, Technology, and Compliance Solutions 31. Intrinseque Health: Best Clinical Supply Chain Solutions Provider 2023 - Singapore Quality-Driven Global Clinical Supply Chain Solutions

NEWS Investing in the home care industry is a smart move with the rise of AI As Artificial Intelligence (AI) and other advanced technologies are continually being developed, various industries, including healthcare, are undergoing revolutionary changes. In this context, entrepreneurs considering long-term investment options are naturally concerned about the potential replacement of certain jobs by machines – posing a difficult decision-making challenge for them. Here, David Glover, Joint CEO of Caremark - one the UK’s leading home care companies, with 120 offices across the UK – discusses how the home care industry is an exception to the rule, and why investing A job robots can’t replace! in a home care business and nurturing care assistants is still a wise choice: “With the increasing demand for home care services, investing in a home care franchise has become a promising opportunity for entrepreneurs. The industry has been growing for years, and with an ageing population, it shows no signs of slowing down. So, while AI may dominate in other sectors, it is unlikely to affect the care sector in the same way. “Certainly, AI can assist with certain aspects of home care, such as monitoring vital signs or providing medication reminders. However, it cannot replace the human connection and emotional support that patients require. In addition to offering everything AI provides, care assistants enable people to truly live, laugh, smile, and share emotions. They facilitate individuals in living life on their own terms – from feeding the birds in their garden, baking their favourite cake, or even flipping through an old photo album together. “Care assistants do more than give exceptional care; they become companions and friends to those they care for. They offer vital emotional support and a listening ear, something that machines cannot replicate. This personal connection is particularly significant for the elderly and individuals with disabilities who may experience isolation or loneliness. The human touch is indispensable for their mental and emotional well-being.

NEWS • 9.2 million waiting for treatment across England, Scotland, Wales & Northern Ireland as of March 2023 • Increase of 3.6 million since the start of the pandemic three years ago • Waiting lists of 7.3 million in England, rising by c.3 million since pandemic as backlog in Wales and Scotland nearly doubles Analysis of English and devolved government data on the NHS crisis from leading independent consultancy Broadstone shows that UK waiting listings have grown by 3.6 million since the start of the pandemic – an increase of 65%. As at March 2023 – the latest up-to-date figures available across all four nations – 9.2 million are now waiting for treatment. It is a number that has risen from 5.6 million just before the pandemic, and by 1.1 million over the past year as the public health system struggles to cope with demand. England accounts for the lions’ share of the list, with English patients representing 79.6% (7.33 million) of the total. The three devolved nations have all seen waiting lists rise significantly, with Wales accounting for 8.0%, Scotland 6.8% and Northern Ireland 5.7% of the total UK backlog. Brett Hill, Head of Health & Protection at Broadstone, said: “We have all read with growing concern the reports of our deteriorating public health system coming out of the four home nations. This analysis looks to bring together the data on a UK-wide level to provide a true picture of the crisis facing the NHS across the United Kingdom. “Taken together, the picture is bleak. Many millions have joined a huge waiting list for treatment since the pandemic and the numbers are still rising despite national and devolved governments pledging to reduce the backlog.” The analysis comes amid continued growth in economic inactivity because of long-term sickness. The latest statistics show that 99,000 more people have become economically inactive in the UK due to ill-health in the six months to February-April 2023. It takes the total number to 2.6 million – a surge of over 427,000 people since the pandemic compared to the 2.12 million as at January-March 2020. Meanwhile the latest PHIN data6 shows that the total number of private healthcare admission in 2022 was the highest since records began at 820,000, up 5% on pre-pandemic levels. The knock-on impact of a struggling public health system is now being felt by businesses throughout the UK, according to Mr Hill. “The problems in the health service cannot be taken in isolation,” he said. “They have a tangible impact in people’s everyday lives, including their professional careers. “Businesses are now starting to recognise the need to invest in the health and wellbeing of their staff to avoid the problems that economic inactivity due to sickness causes them, especially in such a tight labour market. “The ability to support workers with private healthcare options, for example, means that employers can keep their staff fit, healthy and productive while avoiding absenteeism. Given the pressures in the NHS seem unlikely to abate in the near-term we expect to see further demand for private health options through the rest of 2023 and beyond.” NHS waiting lists surge past 9.2 million across the UK “Investing in the home care industry not only makes financial sense but also contributes to improving lives. By supporting home care workers, investors play a role in enhancing society as a whole. They provide individuals with the care and support they need to live fulfilling lives, empowering them to maintain their independence and dignity. “In conclusion, while AI may continue to advance and reshape the world as we know it, the home care industry will always require the human touch. Therefore, investing in this industry is a prudent decision, as it offers both financial returns and the opportunity to contribute to the overall well-being of society. Care assistants are instrumental in ensuring that individuals can continue to enjoy the richness of life.”

6 Nov22096 In addition to its customer-facing products, Dynamic DNA also provides a full range of biomedical research services for pharmaceutical testing, disease research, product testing, gene expression analysis, and more. It works with businesses to develop experimental designs that meet their needs, while continuing to engage in its own independent research projects. The team at Dynamic DNA seek to advance knowledge in biomedicine, writing about their discoveries to share their knowledge with the industry. Importantly, Dynamic DNA is certified by CLIA and accredited by the College of American Pathologists. Its staff are highly qualified and experienced, having worked for over 40 years in research, testing, pathology, and crime laboratories. The team have had several articles published in top scientific journals and have provided expert DNA testimony in federal and international court systems. This means that they can truly be trusted to fulfil the cellular, molecular, and microbiological needs of any individual or business. This incredible team of staff carry out their work within the Dynamic DNA CAP accredited and CLIA certified facility, following the latest regulations and meeting the highest of testing standards. Unlike its competitors, Dynamic DNA does not outsource services, instead all of its testing is completed in-house, where quality can be monitored. This enables the lab to guarantee accurate test results and faster turnaround times, while offering lower prices than others. Furthermore, as a private laboratory, Dynamic DNA does not share its customers’ DNA with any public databases or sources. Dynamic DNA is proud of the fact that it makes complex DNA data easy to understand for its customers. Using its interactive and visual reporting system, where information is securely stored, the company translates customers’ results into plain English, providing clear explanations and recommendations for action moving forward. Considering the affordable yet high-quality nature of its services, it’s simply no surprise that Dynamic DNA has been awarded Best Supplier of At-Home DNA Testing Kits in the GHP Global Excellence Awards 2023. “I couldn’t be happier with the team we’ve created and what we’ve achieved in our first 8 years,” comments Austin O’Reilly, CEO and Scientist at the company. “At Dynamic DNA, we support innovation and accept new challenges, which allows our team to develop new tests and opportunities that support our goals as a company.” Moving on from its success in the Global Excellence Awards, Dynamic DNA plans to leverage the power of DNA microarrays to push the boundaries of clinical and direct-to-consumer genetic testing in the coming years. It aims to offer larger datasets than its competitors and make mass data accessible to everyone, without the need for expensive large-scale sequencing. Furthermore, the company is excited by the development of polygenetic risk score (PRS) analysis, which can inform patients Dedicated to improving the health, wellness, and beauty of individuals across the world, Dynamic DNA Laboratories is a biotechnology company offering DNA testing products that analyse customers’ genetic code to provide a comprehensive insight into their health, nutrition, and fitness. For its outstanding products and services, the company is proud to have won Best Supplier of At-Home DNA Testing Kits in the GHP Global Excellence Awards 2023. Dynamic DNA Laboratories is a state-of-the-art, fully functioning genetics, microbiology, cellular, and microscopy lab that specialises in advanced DNA testing. It was founded based on the idea that knowledge is power and that, by thoroughly exploring their genetic code, people can make small changes that will noticeably improve their lifestyle. The company strives to promote positive change by helping its customers better understand themselves, enabling them to lead healthier and happier lives. To do this, Dynamic DNA delivers a range of services, including ancestry testing, disease predisposition reporting, proactive health panels for nutrition, fitness, and skin, cannabis DNA panels, personalised medicine reporting, paternity and relationship testing, as well as unknown sample identification. Whether customers are looking to take a personalised approach to fitness or trace their family’s past, Dynamic DNA offers affordable yet advanced genetic services, enabling them to make personal discoveries and accomplish their goals. Those who are interested in its services are invited to browse a selection of DNA testing kits on the easy-to-use Dynamic DNA website. When a customer purchases a kit, it will arrive between three and five business days after the order is placed. Then, customers will provide a simple cheek swab, which can be collected in the comfort of their own home and sent back to the company in a pre-paid mailer. When the laboratory receives the sample, the customer’s DNA will be analysed by expert scientists. Within three to four weeks, customers will be able to access their results through Dynamic DNA’s secure online portal. On the Dynamic DNA website, customers can also find information about its one-of-a-kind DNA portraits, which are made with electron microscopes to capture an individual’s unique genetic code. Using only a cheek swab, the company brings life to art with each piece of high-definition microscopic artwork it creates. Feb23476 At-Home DNA Testing: Know Yourself Better in Four Steps

GHP Q2 2023 of their genetic risk of developing some of the most common diseases in the world, early enough for preventative action to be taken. Dynamic DNA is an early adopter of this technology, which utilises a cost-effective form of DNA analysis, making it feasible for any budget. PRS has the potential to put clinical genetic testing into the hands of physicians and patients across the country. We congratulate Dynamic DNA Laboratories on winning Best Supplier of At-Home DNA Testing Kits, and we look forward to seeing how these fascinating developments unfold in the years to come. Contact: Karen Fackler Company: Dynamic DNA Laboratories Web Address:

8 GHP Q2 2023 Founded in 2021, Creasallis is an innovative, creative, antibody solutions company. It has introduced the patented tumour antibody penetration technology CreaTap with plug-and-play capabilities. We are thrilled to be able to take look at what the company is up to, following its award as Best Antibody Solutions Company 2023 – Cambridgeshire. Creasallis is the creative antibody solutions company, with a debut technology known as CreaTap. This is a single plug-andplay solution to help improve the penetration of antibodies into the tumour microenvironment. The company consists of a team of antibody engineers who have been developing antibodybased therapies for the last 17 years. Its ambition is to create truly innovative medicines, but within the pharmaceuticals/biotech sphere innovation can be somewhat limited. Creasallis is the result of this need to create innovative solutions within biotech, but also to dictate a culture of teamwork and accountability. At Creasallis every employee shows up as a leader every day. Creasallis started life as an idea without any data. Its founding members came from an industry where there was no easy way to create a company inclusive of protecting the IP. For this reason, it had to raise a pre-seed round based only on an idea – but this is what happened. It successfully raised a $1 million VC-backed round, all because it had a solution that was simple and easy to understand. Having a team with experience and know-how when it came to delivering drug molecules was certainly a helpful advantage, and meant that Cresallis really stood out in the industry. Cresallis’s CEO and leader Zahra Jawad takes a servant leadership approach, as she has done throughout her career. Her ability to create an inclusive team is an excellent way to ensure that everyone feels ownership, and is part of the success of the company. Responsibility and accountability are owned by individuals, but any errors or mistakes are not tainted. Rather, these occurrences are seen as a chance to grow personally, and also to investigate and understand whether the fault lies within the system itself. Everyone has each other’s backs at Creasallis, with no one team made to feel superior/inferior in comparison to others. Creasallis’s USP is the innovative way it addresses the bottleneck of antibody drug penetrability through a solution that is applicable to all antibody-based therapeutics. This includes monoclonal antibodies, bispecifics, antibody drug conjugates, and any other antibody fragment type technology or platform. As the team is experienced in knowing how to develop antibody-based technologies, it is able to rapidly develop its CreaTap antibodies giving superior tumour penetration. Creasallis has future plans to deploy a hybrid-based approach to developing its own internal pipeline of oncology drugs with enhanced tumour penetration. It hopes to collaborate with key strategic partners to seek In vivo and clinical efficacy. It has a 5-year plan to develop an antibody development pipeline around the technology to enable it to rapidly develop oncology-based drugs. All in all, absolutely outstanding stuff! Company: Creasallis Web Address: Contact Name: Zahra Jawad Game-Changing Antibody Solutions Mar23543 “The CreaTap technology is a modification of an antibody to enable it to enter the tumour micro environment and penetrate the tumour deeper. We have adapted the technology so it can be applied to any antibody isotype, making it a single plug and play technology.”

9 GHP Q2 2023 Clinisys is a global provider of intelligent diagnostic informatics solutions and expertise designed to redefine the modern laboratory, across healthcare, life sciences, and public health. Millions of diagnostic results and data insights are generated every day using Clinisys’ solutions in over 3,000 laboratories across 34 countries. Clinisys recently received recognition in the Global Excellence Awards 2023, where it was labelled the Best Healthcare Informatics Digital Platform – UK. Here we learn more about how the deployment of its solution,WinPath has enabled Black Country Pathology Services to realise its vision of a “world-class” laboratory network. Transforming Laboratories Globally lack Country Pathology Services (BCPS) is part of a major, national initiative to reorganise pathology services in England. Following a landmark report by Lord Carter of Coles, NHS Improvement instituted a programme to create 29 pathology networks to consolidate labs and standardise working practices. The aims of the programme are to make best use of scarce staff and resources, to improve efficiency and quality, and to make sure pathology can respond to the changing needs of the NHS while offering the latest tests and services. BCPS was set up in 2018 to further these aims for its four partner trusts: The Dudley Group NHS Foundation Trust, The Royal Wolverhampton NHS Trust, Sandwell and West Birmingham NHS Trust, and Walsall Healthcare NHS Trust. It also serves 1,000 GPs. It operates a central hub at New Cross Hospital, part of The Royal Wolverhampton NHS Trust and four essential services labs at acute hospitals in Birmingham, Dudley, Sandwell, and Walsall. The network is deploying Clinisys WinPath at all five labs and all pathology disciplines. In total, BCPS conducts 22 million tests per year for a core population of 1.5 million people – and it does so in a way that was described as “world-class” by Lord Carter, when he visited the hub in 2021. BCPS has taken the lessons of Lord Carter’s report to heart as it has developed its network and operating model. To create the most efficient, highest quality service possible, it has designed and executed an extension to its state-of-the-art pathology building at New Cross Hospital in Wolverhampton, to enable it to handle a much larger volume of samples. It has also invested in a single laboratory information system and plans to buy completely new equipment for the hub and its four essential services laboratories. Operational manager Graham Danks says, “The Carter Report has been our model, and we have done the whole thing: the staff, the building, the IT, the equipment. “The IT and the equipment are essential, because we want to build a virtual laboratory, so staff can go from Lab A to Lab B and see no difference in terms of the systems and equipment they use and the processes they follow to do things.” In autumn 2018, BCPS decided to go with Clinisys as the provider of its single LIMS. It opted to take WinPath as a hosted solution and deployed a wide area network to create the fast links needed for constant uptime and rapid access. At the same time, it started to prepare for deployment, by drawing up a single Black Country catalogue for tests and services, coded using the national standard, SNOMED CT, and agreeing harmonised working processes with the different pathology disciplines. “We put people in a room and gave them tea and biscuits and told them they couldn’t come out until they agreed,” Graham jokes. “However, it is an essential step. You standardise your working processes and then you execute them through the LIMS.” BCPS was planning a big-bang go-live for Clinisys WinPath when winning a HPV testing contract and the arrival of Covid-19 forced a rethink. Nick Fudger, senior ICT programme manager, says that to take up the HPV contract, the network had to build new testing facilities, and link-in more than 1,000 sites doing point of care testing. All of which made the implementation of the LIMS in cellular pathology a priority. Nick says, “In the end, we went live with CellPath a year and a day after contract sign. That was at the hub, closely followed by the essential services lab.” Just a few weeks later, the outbreak of the pandemic focused attention on microbiology. Nick says it became imperative to consolidate microbiology services at Wolverhampton and Walsall, because they had high-throughput Covid-19 test analysers, so they became the next priority for go-live. The implementation programme adopted a remote working model. In the face of considerable adversity, this delivered a second go-live in June. “We made the new model work,” says Nick. “We went live with microbiology and shortly after that we went live with the whole of blood sciences. It was a notable achievement, and one that we have been able to build on, subsequently.” By September 2021, BCPS was nearing the end of its WinPath rollout at its central hub in Wolverhampton and its ‘hot’ lab in Walsall. Graham Danks says, “The big benefit has been that we have been able to use this technology to deliver that hub and spoke model of working. It has enabled us to achieve our vision of moving work from site to site, and that is working very well. “We are also making the savings in terms of equipment and staffing that we anticipated in the original plan. We were expecting to save 10-15% per year, and the IT system enables us to do that, by standardising equipment and workflow.” If Graham has one criticism, it is that Clinisys could help customers to get the most out of the powerful rules-engine in WinPath. However, he is pleased with the other benefits that BCPS has derived from using a modern, interoperable LIMS. For example, the network has started to use some of the alerting functionality in WinPath to flag results that might need rapid or further review. It has also been able to interface WinPath to the three electronic patient records in use at its acute trusts, and to the wide variety of record systems used by community and specialist services, such as maternity and sexual health. This makes it much easier for clinicians to view test results alongside a patient’s medical history when planning or delivering care. Lord Carter of Coles praised BCPS during a visit to promote national pathology week in 2021. He was shown innovations such as barcoded tubes for laboratory samples, which allow information to be scanned into WinPath, the full automation of the lab service, and the LIMS integration with local electronic patient record systems. “Deploying technology is the only way forward, and this is wonderful to see,” he says. “Trusts in other parts of the country have done it, but very few have done it as well as this.” Company: Clinisys Email: [email protected] Website: B Apr23683

10 GHP Q2 2023 Based on two decades of research and innovative technology, Aiberry’s platform is an AI-powered assessment tool designed to objectively and reliably assess mental health conditions. The platform is a valuable tool for healthcare providers, increasing access to care, enhancing early detection, and resulting in better treatment outcomes for patients. The company has been awarded Most Pioneering Behavioural Health Assessment A.I Platform, USA, in the GHP Global Excellence Awards 2023. The Future of Mental Health Assessment: AI-Powered Screening ver a decade ago, a group of professors and students from Oxford University and the University of Paris hypothesised that depression could be detected by analysing the unique muscles in the face. Later, this theory evolved to consider the insights that could be gained from voice and word context analysis. Throughout the 2000s, Newton Howard, Soujanya Poria, and Navonil Majumder dedicated boundless research to perfecting this science and developing it into a proven methodology for detecting mental illnesses. Later, this methodology was used to create Aiberry’s patented AI technology, which works by analysing words, tone of voice, and facial expressions to screen for a range of mental health conditions. The platform’s friendly virtual therapeutic assistant, Botberry, engages users in conversation to gain an insight into their mental health. It can track trends and monitor progress over time, ensuring patients receive timely intervention followed by the ongoing support they need. While other companies have simply digitalised paper questionnaires, Aiberry is the only company on the market that is currently fully revamping the way assessments for mental health are carried out. Where traditional mental health screening practices are tedious, subjective, and error prone, Aiberry’s screening solution is objective, reliable, and based on just a short conversation. It provides clinicians and mental health professionals with a comprehensive overview of their patient’s mental health, enabling them to detect depression and anxiety early. Furthermore, Aiberry is proud to be the only product of its kind that delivers over 90% accuracy in detecting the entire range of the depression spectrum, from mild to severe. Its revolutionary solution addresses the mental health crisis as well as the provider shortage. It also improves outcomes and enhances the patient experience. By eliminating cumbersome administrative tasks and streamlining the intake process, Aiberry has helped its partnered recovery centres experience significant time savings and improved patient interactions. One centre expressed that the collaboration has resulted in a remarkable reduction of over 30 minutes in their intake sessions. The extra time saved by therapists can instead be spent engaging in quality, meaningful, and personal conversations with their clients right from the beginning. The centres can therefore prioritise building strong therapeutic relationships and delivering tailored care to those in need. As well as in healthcare settings, Aiberry can be effectively used in the workplace, where employers can offer it to staff as part of their benefits packages. After they complete the assessment, employees can access a range of self-guided tools and tele-mental health options, provided by their employer. This enables leaders to support the mental health of their staff to build strong, productive teams. The leadership at Aiberry has played a pivotal role in helping the company achieve what it has so far. With a strong commitment to diversity and passion, its leaders foster a culture of positivity and inclusivity. This has truly been instrumental in the success of the business and its product, since a diverse team brings fresh perspectives and innovative ideas. This type of creativity is essential in the ever-evolving field of behavioural health. Rather than relying solely on industry experience, they seek individuals who align with the culture and demonstrate potential. This approach ensures the maintenance of a vibrant and energetic environment and boosts the development of the business. At Aiberry, the leadership team also values work-life balance and the importance of celebrating small wins. By taking the time to encourage and build personal friendships within the team, they strengthen the bonds between staff and create a sense of unity and camaraderie. This also promotes resilience and flexibility as staff are more likely to support one another during personal challenges or absences, ensuring that productivity and morale remain high. As a result of its revolutionary patented AI technology, Aiberry has been awarded Most Pioneering Behavioural Health Assessment A.I Platform, USA, in the GHP Global Excellence Awards 2023. Moving forwards, Aiberry’s ambition is to leave behind outdated paper forms and establish its mental health AI solution as the gold standard in assessments. By striving for global accessibility, Aiberry is dedicated to contributing towards early detection, ensuring that individuals worldwide have the opportunity for timely intervention and improved outcomes in behavioural health. Contact: Jennifer Nguyen Company: Aiberry Web Address: O Apr23564

11 GHP Q2 2023 for its team, including a Leadership Academy and Thrive events, designed to celebrate successes and enrich the personal and professional experiences of the team. Its culture is built around its mission to improve access to quality therapy and mental healthcare. Keeping culture at the heart of Therapy Brands means cultivating an environment of genuine respect, both throughout the Therapy Brands team, and towards all of its customers. This is something that is at the forefront of the company’s activities every day, as it delivers its valuable services to patients, clients, and to society. When it comes to recruiting new staff to the team, Therapy Brands looks for a skill set that is varied and diverse. It wants to find people with a passion that connects to its mission to help increase access to all types of therapy. Its main focus, however, is always to nurture and retain team members, hence its development and engagement activities. The team has helped the company to win multiple prizes, such as the recent Comparably award for Best Company Outlook, Culture, and Diversity. Therapy Brands is always working to try and enhance the products it has on offer, which is something it will continue to do in the coming year with the introduction of its new UI/UX interface. This will improve customers’ experience through enhanced billing, patient portals, and better business intelligence capabilities. Such expanded functionality is a direct result of customer feedback Therapy Brands has taken onboard. The company uses such feedback constructively to help it prioritise goals in its product roadmap. The end result is a high value practice management system that’s easy to use, fast to deploy, and gives practitioners more time to spend with their patients. Company: Therapy Brands Web Address: Contact Name: Nicole Lininger Therapy Brands high-value practice management software is created by and for therapists and provides access and treatment for over half a million patients every month. As winners of the Best Practice Management Software Company 2023 – USA, we decided to take a closer look at how the company operates. Therapy Brands Holdings LLC is the leading healthcare IT partner for mental health, behavioral health, substance abuse, and rehabilitative therapy. Its purpose-built practice management software solves scheduling, documentation, revenue, and data solutions driving exceptional clinical and financial outcomes. Therapy Brands is the trusted partner of thousands of therapy providers who rely on its solutions to simplify administration, improve revenues, and enable them to focus on patient care. Founded in 2013, Therapy Brands has grown to include a wide range of solutions specifically designed for practices who specialize in mental and behavioral health. This includes substance use recovery, applied behavioral analysis, as well as physical, speech and occupational therapies. The company today serves more than 200,000 providers, nationwide, across its product portfolio. Working in such a vital sector it is significant that the all-in-one practice management software the company employs is userfriendly and boasts all the features a provider needs to run a mental and behavioral health practice. Therapy Brands realizes there is no one-size fits all within the industry, but instead it offers a myriad of options that ensure practitioners only pay for the features they need. However, it also allows room for their clients to grow and change at their own pace. Therapy Brands makes switching easy and promises to have its providers up and running in no time. It offers a free 21-day trial to allow providers to familiarize themselves with the software before deciding. Therapy Brands understands that organisations are trending towards delivering multiple types of services. For example, they may offer mental health and substance use recovery, alongside primary care, and other services. Therapy Brands continues to enhance its products, enabling providers to use a single platform for all the different types of services they offer. As far as the company’s success goes, Therapy Brands strongly believe it is driven by its team members. The services it offers always begins with true partnership, and its internal team does care deeply about making a positive impact on those it serves. Therapy Brands provides extensive development and engagement opportunities Practice management software made easy. Apr23103

12 Western Fjords Advanced Technologies LLC specialise in the development of novel therapeutic strategies based on disease-specific apoptosis. It has developed a unique prototype to provide a solution in the quest for curative cancer treatment which minimises systemic side effects. In terms of expansion, this working modular concept can also be tailored to the specifications of other diseases. Most Innovative Novel Therapeutics Developer 2023 - Nordics estern Fjords Advanced Technologies LLC was founded in 2008 with the primary purpose of conveying theoretical disease-specific induction of apoptosis, with curative intent, into routine bedside practice. Apoptosis refers to a natural form of cell death in which a cascade of intracellular molecular steps ultimately lead to its death. It is a normal and highly regulated element of an organism’s growth and development, which the body uses to get rid of unneeded or abnormal cells. It is used in early development to eliminate unwanted cells, for example those between the fingers of a developing hand. In adults, the process of apoptosis is used to rid the body of cells that have been damaged beyond repair. It also plays an important role in cancer, for example to eliminate cells that contain potentially dangerous mutations. The process of apoptosis may be blocked in pre-cancerous cells, and if a cell’s pro-apoptotic function is not working properly it can grow and divide uncontrollably, ultimately creating a tumour. Apoptosis is one of those rare instances where the death of a cell (the cell sacrifices itself for the greater good) is to the benefit of the organism as a whole. Dr. Thor Hoegnason, of Western Fjords Advanced Technologies LLC, has combined experience of molecular biology Stateside, in addition to his neurosurgical training on both sides of the Atlantic. This is where the foundations of the company’s corporate mission can be traced back to. Henceforth, Western Fjords Advanced Technologies LLC is primarily dedicated to the development of bench-to-bedside curative treatment of neoplasms of the central nervous system (CNS). In 2011 Western Fjords Advanced Technologies LLC succeeded in the recombinant expression of a fully humanized, tumour-specific pro-apoptotic chimera targeted against WHO Grade II-IV Astrocytomas, with emphasis on the most malignant variant of the astrocytomas, Glioblastoma Multiforme (WHO Grade IV). Using human host cells for recombinant expression and target-specific conditions for extraction and purification of the products 3-Dimensional construct integrity and thus, function, is ensured. Thus, Western Fjords Advanced Technologies LLC has developed a highly potent disease specific therapeutic prototype, easily modified to expand the therapeutic spectrum to additional diseases. The realm of biopharmaceuticals is both vast and yet still relatively young, growing exponentially, with numerous novel products having reached the bedside in recent years. Approaches which may have been considered inconceivable a decade or two ago are now part of the clinician’s daily routine, vastly improving patient quality of life and survival. From the perspective of the start-up, long-term venture capital remains somewhat elusive as Bob Hope once quipped at one of the Oscar Awards Ceremonies he hosted, “so close yet so far away”. Western Fjords Advanced Technologies LLC’s unique marketing strategy consists of the development of a product pipeline of disease specific pro-apoptotic molecules, with curative intent. The therapeutic spectrum ranges from highly malignant brain tumours, which currently entail a terminal prognosis, to a range of chronic ailments with significant comorbidities and decreased, long-term quality of life. All of the company’s products are constructed using human subunit, thus minimizing adverse immune reactions. Its main product, the TAG GB4, is targeted against WHO Grade II-IV Astrocytomas. It works by selectively introducing a constitutively activated pro-apoptotic sentinel into the target cell cytoplasm, to induce apoptosis irrespective of the malignant cells’ metabolic state, cell-cycle or p53 status. Western Fjords Advanced Technologies is a private limited liability company which specialises in the development of novel therapeutic strategies based upon disease-specific induction of apoptosis. It places a special emphasis on the design, development, and marketing of curative forms of treatment against WHO Grade II-IV Astrocytomas and other primary brain tumours. Western Fjords Advanced Technologies LLC has developed a working modular concept, easily tailored to specifications of other diseases, which leads to the construction of an indication-based product pipeline. First there’s the primary construct, TAG GB4, which is targeted specifically against WHO Grade II-IV Astrocytomas. Secondly, the construct has been modified to specifically bind to other primary brain tumours, TAG EP3 and TAG MB1, both of which have been designated orphan disease status. Thirdly, the disease spectrum has been further expanded towards both chronic and malignant diseases of the integument. Fourthly, a prophylactic variant, TAG SC1, has been developed, targeted against a common, global neoplasm. This variant is designed to supplement existing products for topical application. W Jan23203

GHP Q2 2023 Western Fjords Advanced Technologies received pre-seed investment to develop and complete preliminary in vitro studies. Currently, opportunities are available for investors for longterm partnering. As this ingenious award-winning company has recently been named as the Most Innovative Novel Therapeutics Developer 2023 – Nordics, for its incredible advances in biopharmaceutical technology, surely new opportunities are not far away. Company: Western Fjords Advanced Technologies LLC Web Address: Contact Name: Thor Hoegnason

14 GHP Q2 2023 Pioneers in the field of clinical ear care, Clearwax Ltd. is dedicated to the design, development, and manufacture of cuttingedge technology for the removal of ear wax. In addition to this, the company trains ear specialists from across the globe to safely and competently perform ear wax removal. As a result of its innovative products and high-quality training for professionals, Clearwax is proud to have won Best Ear Wax Removal Specialists in the GHP Global Excellence Awards 2023. Many GP practices in the UK no longer offer ear syringing or irrigation services, leaving a growing number of people across the country to suffer with untreated impacted ear wax. As a result, Clearwax strives to combine the best ear care professionals with the latest technology and clinical evidence to provide safe, simple, and effective ear wax removal services. Those who believe they require ear wax removal can identify their local specialist on the Clearwax website, using its ‘find a specialist’ feature. All of Clearwax’s approved ear wax removal specialists have been successfully trained and certified by an accredited ear wax removal training course or programme. Many are also qualified medical and healthcare professionals who are registered with their relevant regulating bodies, including Audiologists, Hearing Care Assistants, Pharmacists, and more. Clearwax aims to achieve clinical excellence in everything it does, working to improve the delivery of clinical ear care around the world through the development of new products, delivery systems, and training programmes. It is continually breaking boundaries to bring to life new ideas and concepts, while maintaining the highest of standards and making no compromises. Since its inception in 2015, Clearwax has become known as a world-renowned pioneer and expert in endoscopic ear wax removal. It trains Audiologists, Hearing Aid Dispensers and ENT doctors to perform endoscopic ear wax removal, including E-suction®, using its specially designed and developed iCLEARscope® video oto-endoscope. This tool is lightweight, portable, and simple to operate. Its tip is placed into the ear canal opening, producing a high definition and wide view of the entire canal and drum to aid in ear wax removal. A significant advantage of this method of removal is the wide field of view it provides. However, some ear wax specialists may struggle to master the technique due to the high level of coordination and precision needed from both hands, with the endoscope held in the nondominant hand and the removal device in the other. With its latest patent-pending innovation, the WAXscope®, Clearwax aims to address this limitation. The instrument is designed to be more user-friendly than an endoscope, with an attached speculum which widens the ear and provides better control. The company believes this tool will revolutionise the provision of clinical ear care across the world. Over the last seven years, Clearwax has worked hard to bring the WAXscope® from concept to market, with total faith in the potential of the instrument. Having faced many obstacles along the way, especially in terms of manufacturing, the company is now very close to launching the product. As a result of the high-quality services provided by the specialists it trains, as well as its innovative inventions which will undoubtedly improve clinical ear care, Clearwax Ltd. has been awarded Best Ear Wax Removal Specialists in the GHP Global Excellence Awards 2023. In the wake of this achievement, the company looks forward to the long-awaited launch of the WAXscope®. It is also working on developing its own range of ear wax removal consumables, which will be both user-friendly and cost-effective. Contact: Neel Raithatha Company: Clearwax Ltd Web Address: Best Ear Care Professionals, Technology, and Clinical Evidence Apr23250

15 GHP Q2 2023 OSSIO® aims to be the gold standard in orthopaedic fixation by encouraging natural bone healing. Following the company’s announcement as Best Orthopedic Medical Device Company 2023 – USA, we have taken the opportunity to take a closer look at this amazing, transformative establishment. Naturally Transformative Bone Healing. eadquartered in Boston, Massachusetts, with development headquarters in Caesarea, Israel, OSSIO is a young, fastgrowing company. It was founded in 2014, beginning with the introduction of a product that was the culmination of years of biomechanical research combined with a vision to begin improving bone healing. Developing the technological basis of OSSIOfiber lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, eliminating metal devices. The company is highly motivated and inspired to heal bone better. Committed to transforming the orthopaedic experience for patients, physicians, and payors (such as private insurance companies), OSSIO’s vision is to provide the first credible replacement to metal implants in the $15B+ orthopaedic fixation market. Its intention is to replace screws, pins, and plates with Intelligent Bone Regeneration Technology. Using OSSIOfiber represents a breakthrough in the industry as an innovative, material platform for orthopaedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility. With OSSIOfiber there is nothing left behind, hence nothing that needs to be removed. By encouraging natural bone healing that, ultimately, stands to eliminate the hardware removal procedures, OSSIO wants to minimise implant-related complications, alleviate pain, and dramatically improve the healthcare economics of orthopaedics. Its bio-integrative implants have both the desired strength and a welcome bio-friendliness. This means they have the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone. The regrowth incorporates and replaces the implant, but without the adverse inflammation and weakness often seen in bio-resorbables, and other bio-composites. It is something that has remained elusive to the industry – until now. OSSIO, with its registered trademark property OSSIOfiber, incorporates intelligent bone regeneration into areas such as nonmetal bunion repairs, non-metal hammertoe repairs, and other non-metal implants for foot pain. The science behind OSSIOfiber is unconventional and state-of-the-art. It’s stronger than cortical bone, stronger and more predictable than polymers alone, and does not have the foreign body reactions, stress-shielding, and potential patient discomfort or removal risks commonly associated with permanent metal hardware. Its strong and Bio-Integrative OSSIOfiber implants provide a unique matrix of fibres made from minerals similar to those already found in bones. This supports strong fixation and enables early bone attachment, as well as gradual bone and tissue ingrowth, and complete integration. This is all done without local or systemic adverse responses. OSSIOfiber offers surgeons and patients the confidence and certainty of a fully Bio-Integrative solution that utilises existing reimbursement and surgical techniques, and provides a more natural healing environment. The materials used are engineered for rapid bone in-growth, regeneration and replacement with a surface texture designed to enable early bone attachment. The 50 percent natural mineral fibre matrix has enhanced mechanical strength and fluid flow for progressive bone integration. It is suspended in 50 percent polymer for a more predictable integration into the local area, without adverse inflammation. It is a strong and Bio-Integrative Fixation designed to restore, regrow, and renew bone without permanent metal hardware. OSSIO’s breakthrough technology is a true innovation that once implanted turns into your own bone. Company: OSSIO Web Address: Contact Name: Alexandria Sooch H Apr23259